A detailed history of Telemus Capital, LLC transactions in Amgen Inc stock. As of the latest transaction made, Telemus Capital, LLC holds 26,326 shares of AMGN stock, worth $6.93 Million. This represents 0.63% of its overall portfolio holdings.

Number of Shares
26,326
Previous 26,678 1.32%
Holding current value
$6.93 Million
Previous $7.17 Million 5.76%
% of portfolio
0.63%
Previous 0.67%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 01, 2024

SELL
$255.7 - $288.46 $90,006 - $101,537
-352 Reduced 1.32%
26,326 $7.58 Million
Q3 2023

Oct 25, 2023

SELL
$218.65 - $271.46 $87,241 - $108,312
-399 Reduced 1.47%
26,678 $7.17 Million
Q2 2023

Jul 10, 2023

SELL
$214.27 - $253.37 $10,499 - $12,415
-49 Reduced 0.18%
27,077 $6.01 Million
Q1 2023

Apr 11, 2023

BUY
$225.79 - $275.2 $47,641 - $58,067
211 Added 0.78%
27,126 $6.56 Million
Q4 2022

Jan 11, 2023

SELL
$229.03 - $291.01 $33,209 - $42,196
-145 Reduced 0.54%
26,915 $0
Q3 2022

Oct 11, 2022

BUY
$224.46 - $253.15 $32,322 - $36,453
144 Added 0.53%
27,060 $6.1 Million
Q2 2022

Aug 10, 2022

BUY
$230.71 - $256.74 $153,422 - $170,732
665 Added 2.53%
26,916 $6.55 Million
Q1 2022

Apr 06, 2022

BUY
$219.27 - $242.57 $899,445 - $995,022
4,102 Added 18.52%
26,251 $6.35 Million
Q4 2021

Feb 01, 2022

SELL
$198.88 - $227.6 $211,011 - $241,483
-1,061 Reduced 4.57%
22,149 $4.98 Million
Q3 2021

Oct 27, 2021

BUY
$212.27 - $248.7 $153,895 - $180,307
725 Added 3.22%
23,210 $4.94 Million
Q2 2021

Aug 09, 2021

BUY
$233.58 - $259.14 $80,818 - $89,662
346 Added 1.56%
22,485 $5.48 Million
Q1 2021

Apr 20, 2021

BUY
$221.91 - $258.6 $266,513 - $310,578
1,201 Added 5.74%
22,139 $5.58 Million
Q4 2020

Jan 28, 2021

SELL
$216.38 - $257.67 $44,790 - $53,337
-207 Reduced 0.98%
20,938 $4.81 Million
Q3 2020

Nov 02, 2020

BUY
$234.65 - $260.95 $276,887 - $307,921
1,180 Added 5.91%
21,145 $4.98 Million
Q2 2020

Jul 17, 2020

SELL
$197.81 - $242.74 $27,693 - $33,983
-140 Reduced 0.7%
19,965 $4.97 Million
Q1 2020

Jun 05, 2020

SELL
$182.24 - $241.7 $38,817 - $51,482
-213 Reduced 1.05%
20,105 $4.62 Million
Q4 2019

Jan 24, 2020

BUY
$189.21 - $243.2 $74,548 - $95,820
394 Added 1.98%
20,318 $4.9 Million
Q3 2019

Nov 12, 2019

BUY
$174.11 - $208.62 $14,451 - $17,315
83 Added 0.42%
19,924 $3.86 Million
Q2 2019

Aug 09, 2019

BUY
$166.7 - $195.41 $28,672 - $33,610
172 Added 0.87%
19,841 $3.6 Million
Q1 2019

May 02, 2019

SELL
$180.87 - $203.88 $15,373 - $17,329
-85 Reduced 0.43%
19,669 $3.74 Million
Q4 2018

Feb 06, 2019

SELL
$178.4 - $208.25 $39,961 - $46,648
-224 Reduced 1.12%
19,754 $3.85 Million
Q3 2018

Oct 23, 2018

BUY
$185.29 - $208.89 $70,780 - $79,795
382 Added 1.95%
19,978 $4.14 Million
Q2 2018

Jul 31, 2018

BUY
$166.05 - $186.51 $19,593 - $22,008
118 Added 0.61%
19,596 $3.62 Million
Q1 2018

Apr 27, 2018

BUY
$169.43 - $198.0 $36,088 - $42,174
213 Added 1.11%
19,478 $3.32 Million
Q4 2017

Feb 02, 2018

BUY
$168.79 - $188.59 $135,707 - $151,626
804 Added 4.36%
19,265 $3.35 Million
Q3 2017

Nov 03, 2017

SELL
$167.29 - $191.0 $155,077 - $177,057
-927 Reduced 4.78%
18,461 $3.44 Million
Q2 2017

Apr 03, 2018

SELL
N/A
-200 Reduced 1.02%
19,388 $3.34 Million
Q1 2017

Apr 03, 2018

BUY
N/A
19,588
19,588 $3.21 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Telemus Capital, LLC Portfolio

Follow Telemus Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemus Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Telemus Capital, LLC with notifications on news.